

Part VI: Summary of the risk management plan

Summary of risk management plan for Decitabine EVER Pharma 50 mg powder for concentrate for solution for infusion (decitabine)

This is a summary of the RMP for Decitabine EVER Pharma 50 mg powder for concentrate for solution for infusion. The RMP details important risks of Decitabine EVER Pharma, how these risks can be minimised, and how more information will be obtained about Decitabine EVER Pharma's risks and uncertainties (missing information).

Decitabine EVER Pharma's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Decitabine EVER Pharma should be used.

Important new concerns or changes to the current ones will be included in updates of Decitabine EVER Pharma's RMP.

I. The medicine and what it is used for

Decitabine EVER Pharma is indicated for the treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organisation (WHO) classification, who are not candidates for standard induction chemotherapy.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Decitabine EVER Pharma 50 mg powder for concentrate for solution for infusion, together with measures to minimise such risks and the proposed studies for learning more about Decitabine EVER Pharma's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g., with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

If important information that may affect the safe use of Decitabine EVER Pharma is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Decitabine EVER Pharma 50 mg powder for concentrate for solution for infusion are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Decitabine EVER Pharma. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

List of important risks and missing information	
Important identified risks	• None
Important potential risks	• None
Missing information	• None

II.B Summary of important risks

The safety information in the proposed product information is aligned with the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Decitabine EVER Pharma.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Decitabine EVER Pharma.

Table of content

Part I: Product(s) Overview	3
Part II: Module SI - Epidemiology of the indication(s) and target population(s)	5
Part II: Module SII - Non-clinical part of the safety specification.....	6
Part II: Module SIII - Clinical trial exposure	7
Part II: Module SIV - Populations not studied in clinical trials	8
Part II: Module SV - Post-authorisation experience	9
Part II: Module SVI - Additional EU requirements for the safety specification	10
Part II: Module SVII - Identified and potential risks	11
Part II: Module SVIII - Summary of the safety concerns.....	12
Part III: Pharmacovigilance Plan (including post-authorisation safety studies)	13
III.1 Routine pharmacovigilance activities.....	13
III.2 Additional pharmacovigilance activities	13
III.3 Summary Table of additional Pharmacovigilance activities	13
Part IV: Plans for post-authorisation efficacy studies	14
Part V: Risk minimisation measures (including evaluation of the effectiveness of risk minimisation activities)	15
V.1. Routine Risk Minimisation Measures	15
V.2. Additional Risk Minimisation Measures	15
V.3 Summary of risk minimisation measures	15
Part VI: Summary of the risk management plan.....	16
II.A List of important risks and missing information.....	17
II.B Summary of important risks.....	17
II.C Post-authorisation development plan	17
II.C.1 Studies which are conditions of the marketing authorisation.....	17
II.C.2 Other studies in post-authorisation development plan	17
Part VII: Annexes.....	18
Annex 1 – EudraVigilance Interface	20
Annex 2 – Tabulated summary of planned, ongoing, and completed pharmacovigilance study programme	21
Annex 3 - Protocols for proposed, on-going and completed studies in the pharmacovigilance plan	22
Annex 4 - Specific adverse drug reaction follow-up forms	23
Annex 5 - Protocols for proposed and on-going studies in RMP part IV.....	24
Annex 6 - Details of proposed additional risk minimisation activities (if applicable).....	25
Annex 7 - Other supporting data (including referenced material)	26
Annex 8 – Summary of changes to the risk management plan over time	27